Introduction – About Cannabinol (CBN)
Cannabinol, commonly known as CBN, is a cannabinoid found in the cannabis plant. It is known for its mild psychoactive properties and acts as a partial agonist at CB1 and CB2 receptors.
CBN is one of the many cannabinoids produced by the cannabis plant, though it is not as concentrated as others like THC or CBD.
Chemical Structure and Interaction
CBN’s chemical formula is C₂₁H₂₆O₂. It interacts with the endocannabinoid system but has a lower affinity for CB1 receptors compared to other cannabinoids, requiring higher doses to achieve its effects.
History and Discovery
CBN was first isolated in 1896 and was the first naturally occurring cannabinoid to be isolated from the cannabis plant. Its structure was fully understood by the 1930s, thanks to the work of chemist Robert Sidney Cahn.
Legal and Regulatory Status in the UK
In the UK, CBN is classified as a Class B controlled substance under the Misuse of Drugs Act, similar to cannabis and THC, making its distribution and possession without authority illegal.
Methods of Consumption
CBN can be consumed in various forms including extracts, oils, and capsules. Due to its mild psychoactivity, dosages tend to be higher than other more potent cannabinoids.
Pharmacokinetics
CBN shows low bioavailability when taken orally, undergoing extensive first-pass metabolism in the liver. It is more effective when inhaled, bypassing the first-pass effect.
Clinical Applications in the UK
Currently, there are no specific medical applications for CBN approved in the UK due to its legal status, but research is ongoing into its potential therapeutic benefits, particularly for sleep and sedation.
Adverse Effects
Like other cannabinoids, CBN can cause side effects such as dizziness, dry mouth, and sedation, especially at higher doses necessary to achieve therapeutic effects.